FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvdomigton, b.o. 20040

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Bailey</u>	<u>Sue</u>				1=	<u> </u>	<u>circ D.</u>	1000	<del>JIUII</del>	7115 1	110.	LEDO	1		X	Directo	r		10% Ov	vner	
(Last) 2273 RE	(Fi	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/22/2014									Officer (give title below)		Other (s below)		specify		
(Street)			20850		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind Line) X	′						
(City)	(S	tate)	(Zip)																		
		Tab	le I - Noi	n-Deriv	ative/	Sec	curitie	s Ac	quire	ed, D	isp	osed o	of, or Bo	enefic	ially	Owned	I				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				ar)   E	Execution f any	A. Deemed xecution Date, any Month/Day/Year)		Code (Instr. 5)					4 and Securiti Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										ode V	,	Amount	(A) (D)	or Pri	ce		action(s) . 3 and 4)			(Instr. 4)	
Common Stock <sup>(1)</sup> 05/22				2/2014	2014			I	A		4,700 <sup>(2)</sup> A		.   ;	\$ <mark>0</mark>	19,100			D			
		7	able II -										, or Ber ble sec			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, 1 (ay/Year) 8	4. Transaction Code (Instr. 8)				6. Date Exercisal Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		E	. Price of perivative security nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Exp Dat	piration te	Title	Amou or Numb of Share	er						
Director Stock Option (right to	\$20.44	05/22/2014			A		9,400		(3	3)	05	/21/2021	Common Stock	9,40	0	\$0	9,400		D		

## **Explanation of Responses:**

- 1. Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. The option will vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders.

## Remarks:

/s/Eric Burt, attorney-in-fact 05/23/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.